Comparative risk of intracerebral haemorrhage between Tenecteplase and alteplase across doses in acute ischaemic stroke: a network meta-analysis of randomized controlled trials

Read full text Summarise with VIRAT
Authors: João Vítor Andrade Fernandes, J. Mancha Ramos, Maurus Marques de Almeida Holanda
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Tenecteplase (TNK) is a potential alternative to standard-dose alteplase (ALT) for intravenous thrombolysis in acute ischaemic stroke (AIS), but its safety may vary by dose. We conducted a systematic literature search in PubMed, Embase, and CENTRAL through 14 February 2025. Interventions included intravenous TNK at 0.1, 0.25, 0.32, or 0.4 mg/kg versus ALT 0.9 mg/kg. Primary outcomes were all intracranial haemorrhage (ICH) and symptomatic ICH; secondary outcomes included modified Rankin Scale (mRS) 0–1 and 0–2, severe adverse events (SAEs), and mortality. A network meta-analysis was performed using a frequentist random-effects model. Eleven randomized controlled trials were included. No significant differences were observed between TNK and ALT for all ICH or symptomatic ICH. TNK 0.25 mg/kg and 0.1 mg/kg consistently ranked higher in safety, while TNK 0.4 mg/kg was associated with numerically greater odds of ICH (I2 = 73.7% for all ICH; 39.7% for symptomatic ICH). TNK 0.25 mg/kg was superior to ALT for achieving mRS 0–1 (OR 1.14, 95% CI: 1.03–1.27). No significant differences were observed in SAEs or mortality, though TNK 0.4 mg/kg ranked least favorably. TNK at 0.25 mg/kg may offer the most favorable balance of safety and efficacy for AIS. In contrast, the 0.4 mg/kg dose was associated with increased haemorrhagic risk and lower safety rankings.

Fields of Study & Subjects

Acute Ischemic Stroke Management Intracerebral and Subarachnoid Hemorrhage Research Acute Myocardial Infarction Research

Publication details

Journal / source
Figshare
Publication date
20 March 2026
Language
EN